Galapagos NV has achieved milestones under its osteoarthritis alliance with Servier, triggering milestone payments to Galapagos totaling $4.7 million. In July 2010, the two companies entered an alliance to develop new medicines for the treatment of osteoarthritis (OA). Galapagos is responsible for the discovery and development of new drug candidates, and Servier has an exclusive option to license them after the completion of Phase I trials. “We are pleased that the molecules derived under the ...